Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
753 results about "Hepacivirus" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Hepacivirus is a genus of positive-sense single-stranded RNA viruses in the family Flaviviridae. The hepatitis C virus (HCV), belonging to the species Hepacivirus C, has humans as its only known natural host, and is associated with hepatitis and hepatocellular carcinoma.
Imidazolidinones as NS3-serine protease inhibitors of hepatitis C virus
InactiveUS6838475B2Reduce frictionReduce wearBiocideOrganic active ingredientsSerine Protease InhibitorsHepacivirus
The present invention discloses novel imidazolidinones which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such imidazolidinones as well as methods of using them to treat disorders associated with the HCV protease.
Owner:SCHERING CORP
Method for the preparation of purified HCV RNA by exosome separation
InactiveUS7198923B1Simple preparation processPromote progressSsRNA viruses positive-senseMicrobiological testing/measurementExosomeBlood plasma
Owner:GRIFOLS WORLDWIDE OPERATIONS +1
Substituted cycloalkyl P1′ hepatitis C virus inhibitors
InactiveUS6878722B2Inhibit functioningEffective treatmentBiocideDipeptide ingredientsHepacivirusVirology
The present invention relates to tripeptide compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. In particular, the present invention provides novel tripeptide analogs, pharmaceutical compositions containing such analogs and methods for using these analogs in the treatment of HCV infection.
Owner:BRISTOL MYERS SQUIBB CO
Inhibitors of serine proteases, particularly HCV NS3-NS4A proteases
The present invention relates to compounds of formula I:or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3–NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
Owner:VERTEX PHARMA INC
Screening methods to identify agents that selectively inhibit hepatitis C virus replication
InactiveUS6030785APrevent dimerizationBlock viral inhibitionFungiSsRNA viruses positive-senseCellular defenseViral infection
The present invention relates to novel methods for identifying antiviral agents which selectively interfere with viral proteins that override the interferon(IFN)-induced cellular defense mechanisms against viral infection. In particular, the present invention relates to screening assays that identify agents which selectively inhibit the interaction between viral proteins containing an interferon sensitivity determining region (ISDR) and IFN-induced PKR protein kinase. The present invention more particularly relates to screening assays that identify agents which selectively inhibit the interaction between hepatitis C virus (HCV) nonstructural 5A protein (NS5A), which contains an ISDR, and IFN-induced PKR protein kinase. The interaction between the viral ISDR and IFN-induced PKR protein kinase results in the override of IFN-induced cellular defense mechanisms to combat viral infection. Therefore the agents identified using the assays of the invention may have utility as antiviral agents.
Owner:UNIV OF WASHINGTON
Methods and compositions for treating hepatitis C virus
InactiveUS20050124532A1Inhibitory activityDetermine the spectrum of activityBiocideSugar derivativesHepatitisModified nucleosides
A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.
Owner:SOMMADOSSI JEAN PIERRE +1
Combinations for HCV treatment
InactiveUS20060003942A1Improve pharmacokineticsImproving the pharmacokinetics of Hepatitis C NS3/4ABiocideOrganic active ingredientsHcv treatmentMonooxygenase
The present invention relates to co-administering a Hepatitis C virus NS3 / 4A protease inhibitor and a cytochrome P450 monooxygenase inhibitor. The combination acts by interfering with the life cycle of the hepatitis C virus and is therefore useful as an antiviral therapy. As such, the combination may be used for treating or preventing Hepatitis C infections in patients. The invention also relates to compositions comprising the combination of inhibitors. The invention also relates to kits and pharmaceutical packs comprising a Hepatitis C virus NS3 / 4A protease inhibitor and a cytochrome P450 monooxygenase inhibitor. The invention also relates to processes for preparing these compositions, combinations, kits, and packs.
Owner:VERTEX PHARMA INC
Anti-Viral Compounds
ActiveUS20100168138A1Lower Level RequirementsOrganic active ingredientsBiocideHepacivirusAnti virals
Owner:ABBVIE INC
Quinoxalinyl tripeptide hepatitis C virus inhibitors
The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof:which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Owner:ENANTA PHARM INC
Inhibitors of serine proteases, particularly HVC NS3-NS4A protease
InactiveUS20050080017A1Inhibit HCV replicationReduce riskBiocidePeptide/protein ingredientsProteinase activityAntiviral drug
The present invention relates to compounds of formula I: or pharmaceutically acceptable salts thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising said compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.
Owner:VERTEX PHARMA INC
Cloned genomes of infectious hepatitis C viruses and uses thereof
InactiveUS6153421ADetermining effectSsRNA viruses positive-senseSugar derivativesNucleic acid sequencingGenome
The present invention discloses nucleic acid sequences which encode infectious hepatitis C viruses and the use of these sequences, and polypeptides encoded by all or part of these sequences, in the development of vaccines and diagnostics for HCV and in the development of screening assays for the identification of antiviral agents for HCV.
Owner:HEALTH & HUMAN SERVICES DEPT OF
Acylaminoheteroaryl hepatitis C virus protease inhibitors
InactiveUS20080039470A1Inhibit serine protease activityInhibitory activityBiocideTripeptide ingredientsProteinase activityIsrapafant
The present invention discloses compounds of formulae I and II, or pharmaceutically acceptable salts, esters, or prodrugs thereof:which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Owner:ENANTA PHARM INC
Methods and compositions for treating hepatitis C virus
InactiveUS20050137161A1Inhibitory activityDetermine the spectrum of activityBiocideSugar derivativesHepatitisModified nucleosides
A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.
Owner:INDENIX PHARM LLC
Compositions and methods for treatment of hepatitis C virus-associated diseases
InactiveUS6284458B1Regulate expressionReduce infectionSsRNA viruses positive-senseGenetic material ingredientsIn vivoHepacivirus
Antisense oligonucleotides are provided which are complementary to and hybridizable with at least a portion of HCV RNA and which are capable of inhibiting the function of the HCV RNA. These oligonucleotides can be administered to inhibit the activity of Hepatitis C virus in vivo or in vitro. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus, and for diagnosis and detection of HCV and HCV-associated diseases. Methods of using these compounds are also disclosed.
Owner:JURIDICAL FOUND THE CHEMO SERO THERAPEUTIC RES INST
Bridged bicyclic serine protease inhibitors
InactiveUS6909000B2Inhibit HCV replicationReduce riskBiocidePeptide/protein ingredientsSerine Protease InhibitorsProteinase activity
The present invention relates to peptidomimetic compounds which inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The compounds of this invention have a bridged bicyclic moiety at the P2 position. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention.
Owner:VERTEX PHARMA INC
Compounds with the bicyclo[4.2.1]nonane system for the treatment of flavivridae infections
InactiveUS20040082574A1Potent and selective activityPotent activityBiocideSugar derivativesPestivirusMedicine
The disclosed invention is a bicyclo[4.2.1]nonane and its pharmaceutically acceptable salt or prodrug, and its composition and method of use to treat Flaviviridae (Hepacivirus, Flavivirus, and Pestivirus) infections in a host, including animals, and especially humans.
![Compounds with the bicyclo[4.2.1]nonane system for the treatment of flavivridae infections](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/48441fda-b6e5-4967-b334-797833136516/US20040082574A1-20040429-C00001.png "Compounds with the bicyclo[4.2.1]nonane system for the treatment of flavivridae infections")
![Compounds with the bicyclo[4.2.1]nonane system for the treatment of flavivridae infections](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/48441fda-b6e5-4967-b334-797833136516/US20040082574A1-20040429-C00002.png "Compounds with the bicyclo[4.2.1]nonane system for the treatment of flavivridae infections")
![Compounds with the bicyclo[4.2.1]nonane system for the treatment of flavivridae infections](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/48441fda-b6e5-4967-b334-797833136516/US20040082574A1-20040429-C00003.png "Compounds with the bicyclo[4.2.1]nonane system for the treatment of flavivridae infections")
Owner:PHARMASSET
Inhibitors of serine protease, particularly hcv ns3-ns4a protease
InactiveUS20090022688A1Reduce riskReduce severityOrganic active ingredientsPeptide/protein ingredientsProteinase activityMedicine
Owner:VERTEX PHARMA INC
Quinoxalinyl tripeptide hepatitis C virus inhibitors
The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof:which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Owner:ENANTA PHARM INC
Yeast-based therapeutic for chronic hepatitis C infection
InactiveUS7439042B2Reduces and prevents HCV infectionSsRNA viruses positive-senseViral antigen ingredientsChronic viral hepatitis CYeast
Disclosed are compositions, including vaccines, and methods for vaccinating an animal against hepatitis C virus (HCV) and for treating or preventing hepatitis C viral infection in an animal. The invention includes a variety of novel HCV fusion proteins that can be used directly as a vaccine or in conjunction with a yeast-based vaccine vehicle to elicit an immune response against HCV in an animal. The invention also includes the use of the HCV fusion gene and protein described herein in any diagnostic or therapeutic protocol for the detection and / or treatment or prevention of HCV infection.
Owner:GLOBE IMMUNE INC
Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
InactiveUS20090005387A1Inhibit serine protease activityInhibitory activityBiocideOrganic chemistrySerine Protease InhibitorsProteinase activity
The present invention relates to compounds, including compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof:which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Owner:ENANTA PHARM INC
Novel inhibitors of secretion of hepatitis b virus antigens
InactiveUS20130303552A1Low serum levelsBiocideOrganic active ingredientsAntigenHepatitis B Virus Antigen
Owner:DREXEL UNIV +2
Aza-peptide macrocyclic hepatitis C serine protease inhibitors
The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof:which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Owner:ENANTA PHARM INC
Hepatitis c virus inhibitors
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.
Owner:ENANTA PHARM INC
Compositions and methods for inhibiting gene expression of hepatitis B virus
The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a Hepatitis B Virus gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Hepatitis B Virus infection using said pharmaceutical composition; and methods for inhibiting the expression of a Hepatitis B Virus gene in a cell.
Owner:ARROWHEAD PHARMA INC
5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
Provided herein are 5,5-fused heteroarylene hepatitis C virus inhibitor compounds, for example, of Formula I, IA, or IB, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.
Owner:INDENIX PHARM LLC
Anti-viral 7-deaza D-nucleosides and uses thereof
The present invention relates generally to anti-viral compounds, particularly anti-viral 7-deaza D-nucleosides and analogues, or derivatives thereof. The invention also relates to the use of such compounds to treat or prevent hepatitis B virus (HBV) infections, and to the use of such compounds to examine the biological mechanisms of HBV infection.
Owner:MIGENIX INC (CA)
Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease
Owner:VERTEX PHARMA INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com